Tag: Cancer: Lymphoma
ASH: Auto-HCT Not Beneficial for Mantle Cell Lymphoma With Undetectable Residual Disease
Overall survival no better for those receiving autologous HCT plus maintenance rituximab versus rituximab alone
Late-Stage Lymphoma Less Likely for Young With Continuous Medicaid Coverage
Those with newly gained Medicaid, with other Medicaid enrollment patterns more likely to present with stage IV lymphoma
Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
Longer progression-free survival seen with nivolumab + doxorubicin, vinblastine, and dacarbazine (AVD) versus brentuximab vedotin + AVD
Liso-Cel Has Favorable Safety Profile for Outpatients With Large B-Cell Lymphoma
Favorable safety profile seen for relapsed/refractory large B-cell lymphoma patients monitored as outpatients or inpatients
Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard...
Most common SPM subtypes were hematologic malignancies followed by solid tumors, nonmelanoma skin cancers
Toxicities Rare After Two Weeks of CAR T-Cell Therapy Infusion
Nonrelapse mortality was driven by ICANS in early follow-up period, followed by infection through three months
Immunoglobulin Replacement Therapy Beneficial for Blood Cancers
Reduction seen in hypogammaglobulinemia, infections or severe infections, and associated antimicrobial use
Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma
Significant overall survival benefit seen for Glofit-GemOx at primary and follow-up analysis
ViPOR Results in Durable Remission in Specific Subtypes of Lymphoma
Complete responses seen in 38 percent of patients, all with non-GCB DLBCL, high-grade B-cell lymphoma with rearrangements of MYC and BCL2 or BCL6
Second Tumors Are Rare After Chimeric Antigen Receptor T-Cell Therapy
Lethal T-cell lymphoma identified in one patient who received axicabtagene ciloleucel therapy for diffuse large B-cell lymphoma
